Drugs /

tno155

Back to Drugs List

Overview

NCI Definition [1]:
An inhibitor of protein tyrosine phosphatase (PTP) non-receptor type 11 (SHP2; src homology region 2 domain phosphatase; PTPN11), with potential antineoplastic activity. Upon oral administration, SHP2 inhibitor TNO155 binds to and inhibits SHP2. This prevents SHP2-mediated signaling, inhibits MAPK signaling and prevents growth of SHP2-expressing tumor cells. SHP2, an oncoprotein overexpressed in a variety of cancer cell types, regulates cell survival, differentiation and proliferation through activation of the RAS-RAF-ERK signaling pathway. SHP2 also regulates programmed cell death 1 (PD-1)-mediated signal transduction and is involved in immune checkpoint modulation.

Clinical Trials

View Clinical Trials for tno155

Tno155 has been investigated in 7 clinical trials, of which 7 are open and 0 are closed. Of the trials investigating tno155, 3 are phase 1 (3 open) and 4 are phase 1/phase 2 (4 open).

KRAS G12C, ALK Fusion, and BRAF Codon 600 Missense are the most frequent biomarker inclusion criteria for tno155 clinical trials.

Colorectal carcinoma, malignant solid tumor, and non-small cell lung carcinoma are the most common diseases being investigated in tno155 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Tno155
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating tno155 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
ptpn11 inhibitor tno155, shp2 inhibitor tno155
Drug Target(s) [2]:
PTPN11
NCIT ID [1]:
C139559

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.